Documented uses of PCI
PCI for in vitro molecule delivery
In vitro data show that PCI can improve the delivery of many types of proteins and many different common gene therapy vectors, and that it works in most cell lines. The following levels of increase in protein delivery, gene transfection and transduction have been achieved:
| Ref. to publications: | ||
| · proteins toxins: | up to 100 times | (1, 4, 6) |
| · immuno- and affinity toxins: | up to 1000 times | (5, 41, 60) |
| · polycationic transfection vectors: | up to 1000 times | (2, 23) |
| · cationic lipid transfection vectors: | up to 5 times | (16, 58) |
| · adenovirus vector: | up to 35 times | (11, 22) |
| · oligonucleotides (siRNA, PNA): | up to 100 times | (19, 40, 57, 58, 62) |
| · small molecule cytotoxic agents: | up to 100 times | (37, 48) |
| · nanoparticles (liposomal, polymeric): | up to 100 times | (28, 61) |
PCI for in vivo drug delivery
In 5 different animal cancer models, the PCI technology has been documented for delivery of proteins, genes and a small molecule cytotoxic drug. For all these classes of molecules, substantial improvments in tumour theapy have been demonstrated, thus:
- with a protein toxin that had no effect on its own, PCI gave a complete and lasting tumour response in about 70 % of the animals (ref publiations: 6, 34).
- with a therapeutic gene (p53) delivered by a nonviral vector, PCI transformed a non-fuctional gene therapy to a very efficient tumour treatment (see fig. 1) (ref. publication: 44).
- with the approved cytotoxic agent bleomycin PCI induced a complete and lasting tumour response in about 60 % of the animals with a bleomycin dose where no such responses were induced by the drug alone (ref. publication: 37).
Development status and plans
- PCI Biotech is developing a patented photosensitiser (AmphinexTM) for clinical use.
- Clincial studies in cancer patients with AmphinexTM and the cytotoxic agent bleomycin is planned to start in 2008.
- PCI Biotech is developing PCI further for delivery of siRNA and other oligonucleotides
Printer-friendly version